Adherence and patients’ experiences with erlotinib.
Completed
- Conditions
- CancerOral chemotherapyErlotinibAdherencePlasma concentrationLongkankerOrale chemotherapieErlotinibTherapietrouwPlasmaconcentratie
- Registration Number
- NL-OMON26332
- Lead Sponsor
- VU medical centre, Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
NSCLC patients starting with erlotinib.
Exclusion Criteria
Younger than 18 year or insufficient knowledge of the Dutch language.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Adherence rate; a patient is adherent with the intake of 85% or more of the prescribed medication;<br /><br>2. Plasma concentration of erlotinib;<br /> <br>3. Number and grade of side-effects.
- Secondary Outcome Measures
Name Time Method 1. Quality of life;<br /> <br>2. Attitude towards disease;<br /><br>3. Beliefs and attitude towards medicines;<br /><br>4. Percentage of dose adjustment;<br /><br>5. Discontinuation.